• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Diabetic Dermopathy in Man With Long-Standing Diabetes Mellitus

News
Article

Numerous brown spots on his leg brought this man with long-standing diabetes mellitus to his physician. He thought the spots were related to trauma.

Numerous brown spots on his leg brought this man with long-standing diabetes mellitus to his physician. He thought the spots were related to trauma.

The patient has diabetic dermopathy. This is a microangiopathy of the small arterioles of the legs, which results in atrophic brown papules.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Impact of Social Determinants of Health on Key Cardiometabolic Measures Amplified by New Research
Intermediate Cardiometabolic Risk: Study Author Explains this "Critical Inflection Point"
Intermediate Cardiometabolic Risk: Study Author Explains this "Critical Inflection Point"
US Cardiometabolic Health at Alarming Suboptimal Levels, Says Lead Author of New NHANES Analysis
US Cardiometabolic Health at Alarming Suboptimal Levels, Says Lead Author of New NHANES Analysis
Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
Kidney Outcomes with Tirzepatide in T2D: Hiddo Heerspink, PhD, PharmD Highlights SURPASS-4 Analysis
Kidney Outcomes with Tirzepatide in T2D: Hiddo Heerspink, PhD, PharmD Highlights SURPASS-4 Analysis
Is There Room for TikTok in Medicine? A Young Clinician Explains
Is There Room for TikTok in Medicine? A Young Clinician Explains
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
SGLT-2 Inhibitors Belong to Patients, Not a Specialty or Primary Care: Experts Discuss
SGLT-2 Inhibitors Belong to Patients, Not a Specialty or Primary Care: Experts Discuss
Related Content
Switching to Tirzepatide Outweighs Escalating Dulaglutide Dose in T2D: SURPASS-SWITCH Trial

Switching to Tirzepatide Outweighs Escalating Dulaglutide Dose in T2D: SURPASS-SWITCH Trial

Sydney Jennings
April 4th 2025
Article

Breaking research presented at ACP Internal Medicine 2025 showed that switching GLP1-RAs resulted in better glucose and weight control among adults with inadequately controlled T2D.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study

ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study

Sydney Jennings
April 1st 2025
Article

Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Oral Semaglutide Lowers Risk of MACE 14% in Adults with T2D, ASCVD and/or CKD: Final Phase 3 SOUL Trial Readout/ image credit American College of Cardiology

Oral Semaglutide Lowers Risk of MACE 14% in High-Risk Adults: Final Phase 3 SOUL Trial Readout

Grace Halsey
March 31st 2025
Article

ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.

Dupilumab is Safe and Effective Across Pediatric Populations with Severe Atopic Dermatitis: New Meta-Analysis

Dupilumab is Safe and Effective Across Pediatric Populations with Severe Atopic Dermatitis: New Meta-Analysis

Grace Halsey
March 31st 2025
Article

Dupilumab significantly improved measures of severe AD, including EASI and IGA, as well as pruritis in pediatric populations aged 6 months to 18 years vs placebo.

© 2025 MJH Life Sciences

All rights reserved.